Novartis’s Rydapt wins EU approval for AML, other diseases

ZURICH (Reuters) – Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals the medicine secured in April.

Reuters: Health News

Leave a Reply